Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP10 | P09238 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275863 | 0.90 | CHRM1 (0.70) | CHRM1ADAM17ALOX5CYP2C9KCNH2 | |
| SCHEMBL17656793 | 0.89 | CHRM1 (0.55) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6892450 | 0.87 | CHRM1 (0.54) | CHRM1ADAM17ALOX5CYP2C9KCNH2 | |
| SCHEMBL12803223 | 0.85 | CHRM1 (0.63) | CHRM1ADAM17ALOX5CYP2C9KCNH2 | |
| SCHEMBL6890744 | 0.85 | CHRM1 (0.46) | CHRM1ADAM17 | |
| SCHEMBL6890091 | 0.82 | ADAM17 (0.41) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL17656772 | 0.79 | ADAM17 (0.47) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2273210 | 0.79 | CHRM1 (0.56) | CHRM1ADAM17 | |
| SCHEMBL2221937 | 0.79 | CHRM1 (0.70) | CHRM1KCNH2 | |
| SCHEMBL12802941 | 0.79 | CHRM1 (0.70) | CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |